HemosprayTM for Gastrointestinal Bleeding From Cancer
Launched by KING CHULALONGKORN MEMORIAL HOSPITAL · Feb 26, 2019
Trial Information
Current as of May 20, 2025
Unknown status
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Acute upper or lower gastrointestinal bleeding
- • Endoscopy shows actively bleeding at index endoscopy (spurting or oozing)
- • Bleeding from malignancy
- Exclusion Criteria:
- • Less than 18 years old
- • Previously included in the trial
- • Eastern Cooperative Oncology Group (ECOG) score 3 or 4
- • Pregnancy/lactation
- • Bleeding from GI sources suspected of not being malignant
About King Chulalongkorn Memorial Hospital
King Chulalongkorn Memorial Hospital, a leading medical institution in Thailand, is renowned for its commitment to advancing healthcare through innovative research and clinical trials. Affiliated with Chulalongkorn University, the hospital integrates cutting-edge medical practices with a robust academic framework, fostering an environment conducive to pioneering clinical studies. With a focus on improving patient outcomes and contributing to global medical knowledge, the hospital engages in a diverse range of clinical trials across various therapeutic areas, ensuring adherence to the highest ethical standards and regulatory guidelines. Through collaboration with healthcare professionals and researchers, King Chulalongkorn Memorial Hospital aims to enhance the quality of care while driving forward the frontiers of medical science.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bangkok, , Thailand
Patients applied
Trial Officials
Rapat Pittayanon, MD
Principal Investigator
King Chulalongkorn Memorial Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials